The activation status and viability of mDCs after 2 h of in vitro infection with different treatments were evaluated by flow cytometry, analyzing the human leukocyte antigen molecule HLA-DR (HLA) (Figure 4A), analyzing the expression of surface markers CD80 and CD86 (Figure 4B and Figure 4C, respectively), and by assessing the percentage of PI+ cells (necrotic cells) (Figure 4D). This evidence concerns the gene CD86 and infection.